Decheng Capital LLC 13F holdings
Decheng Capital LLC reported 14 positions with a total reported value of $731.7M as of 2026-06-30, in its 13F for Q2 2026, filed 2026-08-14. Top holdings by reported value: CGON CG ONCOLOGY INC (61.9%), NUVB Nuvation Bio Inc. (20.1%), AARD AARDVARK THERAPEUTICS INC (3.1%), ACRS Aclaris Therapeutics, Inc. (2.9%), UPB Upstream Bio Inc. (2.6%). Against 2026-03-31 it opened 1 new position and exited 1. Next 13F due by 2026-11-14, the legal deadline 45 days after the quarter ending 2026-09-30.
Email me when Decheng Capital LLC files its 13F
A free account follows up to 10 funds. New 13F filings arrive in your daily or weekly digest. No password and no card.
Top holdings
14 largest of 14 positions · reported value as of 2026-06-30
| Holding | Shares | Reported value | % of portfolio |
|---|---|---|---|
| CGON CG ONCOLOGY INC | 6,371,669 | $452.7M | 61.9% |
| NUVB Nuvation Bio Inc. | 25,954,439 | $147.4M | 20.1% |
| AARD AARDVARK THERAPEUTICS INC | 3,917,299 | $22.6M | 3.1% |
| ACRS Aclaris Therapeutics, Inc. | 4,041,736 | $21.4M | 2.9% |
| UPB Upstream Bio Inc. | 2,724,868 | $18.9M | 2.6% |
| RCUS Arcus Biosciences, Inc | 464,779 | $14.3M | 2.0% |
| EQ Equillium Inc. | 4,447,308 | $14.2M | 1.9% |
| RVMD REVOLUTION MEDICINES INC(NSM) | 52,667 | $9.9M | 1.3% |
| LYEL Lyell Immunopharma, Inc. | 692,050 | $9.7M | 1.3% |
| BYSI BeyondSpring Inc. | 3,800,702 | $6.7M | 0.9% |
| ZNTL Zentalis Pharmaceuticals Inc. | 1,323,327 | $6.4M | 0.9% |
| NAMS NEWAMSTERDAM PHARMA CO NV | 176,887 | $6.0M | 0.8% |
| PYXS Pyxis Oncology, Inc (formerly Apexigen) | 326,810 | $983.7K | 0.1% |
| TNGX TANGO THERAPEUTICS INC | 20,000 | $625.2K | <0.1% |
SEC FORM 13F · Q2 2026 · VALUES AS REPORTED, NOT PRICES
New positions this quarter
Held at 2026-06-30, not at 2026-03-31 · 1 in all · reported value as of 2026-06-30
| Holding | Shares | Reported value | % of portfolio |
|---|---|---|---|
| TNGX TANGO THERAPEUTICS INC | 20,000 | $625.2K | <0.1% |
Sold out
Held at 2026-03-31, gone by 2026-06-30 · 1 in all · reported value as of 2026-03-31
| Holding | Shares 2026-03-31 | Reported value | % of portfolio then |
|---|---|---|---|
| KRYS KRYSTAL BIOTECH INC | 7,300 | $1.9M | 0.3% |
Biggest increases and decreases
Positions held at both quarter ends, by change in shares · reported value as of 2026-06-30
Increases
No position was increased.
Decreases
| Holding | Shares 2026-03-31 | Shares 2026-06-30 | Change | Reported value |
|---|---|---|---|---|
| RVMD REVOLUTION MEDICINES INC(NSM) | 93,500 | 52,667 | -43.7% | $9.9M |
| NAMS NEWAMSTERDAM PHARMA CO NV | 325,057 | 176,887 | -45.6% | $6.0M |
| RCUS Arcus Biosciences, Inc | 477,819 | 464,779 | -2.7% | $14.3M |
CIK 2010850 · 13F FILINGS ON EDGAR · INFORMATIONAL ONLY
